CervoMed Inc
CRVO7.600USD
-0.300-3.80%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
70.32MMarket Cap
LossP/E TTM
More Details of CervoMed Inc Company
CervoMed Inc. is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. It focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB.
CervoMed Inc Info
Ticker SymbolCRVO
Company nameCervoMed Inc
IPO dateNov 09, 2016
CEOAlam (John J)
Number of employees15
Security typeOrdinary Share
Fiscal year-endNov 09
Address20 Park Plaza, Suite 424
CityBOSTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02116
Phone16177444400
Websitehttps://cervomed.com/
Ticker SymbolCRVO
IPO dateNov 09, 2016
CEOAlam (John J)
Company Executives of CervoMed Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Joshua S. Boger, Ph.D.
Dr. Joshua S. Boger, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
1.06M
--
Mr. John J. Alam, M.D.
Mr. John J. Alam, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
753.29K
+3.08%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Independent Director
Independent Director
16.44K
--
Ms. Kelly Blackburn
Ms. Kelly Blackburn
Executive Vice President - Clinical Development
Executive Vice President - Clinical Development
13.67K
--
Ms. Jane H. Hollingsworth, M.D.
Ms. Jane H. Hollingsworth, M.D.
Independent Director
Independent Director
899.00
--
Mr. David Quigley
Mr. David Quigley
Director
Director
--
--
Mr. William R. Elder
Mr. William R. Elder
Chief Financial Officer, General Counsel, Corporate Secretary
Chief Financial Officer, General Counsel, Corporate Secretary
--
--
Dr. Marwan Noel Sabbagh, M.D.
Dr. Marwan Noel Sabbagh, M.D.
Independent Director
Independent Director
--
--
Dr. Claudia Ordonez, M.D.
Dr. Claudia Ordonez, M.D.
Senior Vice President - Medical Science
Senior Vice President - Medical Science
--
--
Dr. Marco Verwijs, Ph.D.
Dr. Marco Verwijs, Ph.D.
Executive Vice President - Technical Operations
Executive Vice President - Technical Operations
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Joshua S. Boger, Ph.D.
Dr. Joshua S. Boger, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
1.06M
--
Mr. John J. Alam, M.D.
Mr. John J. Alam, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
753.29K
+3.08%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Independent Director
Independent Director
16.44K
--
Ms. Kelly Blackburn
Ms. Kelly Blackburn
Executive Vice President - Clinical Development
Executive Vice President - Clinical Development
13.67K
--
Ms. Jane H. Hollingsworth, M.D.
Ms. Jane H. Hollingsworth, M.D.
Independent Director
Independent Director
899.00
--
Mr. David Quigley
Mr. David Quigley
Director
Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Boger (Joshua S)
11.43%
AWM Investment Company, Inc.
9.33%
Gregoire (Sylvie L.)
8.14%
Alam (John J)
8.14%
Morgan Stanley & Co. LLC
4.43%
Other
58.53%
Shareholders
Shareholders
Proportion
Boger (Joshua S)
11.43%
AWM Investment Company, Inc.
9.33%
Gregoire (Sylvie L.)
8.14%
Alam (John J)
8.14%
Morgan Stanley & Co. LLC
4.43%
Other
58.53%
Shareholder Types
Shareholders
Proportion
Individual Investor
32.17%
Investment Advisor/Hedge Fund
11.21%
Investment Advisor
6.37%
Research Firm
4.45%
Hedge Fund
1.42%
Other
44.38%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
123
2.18M
45.61%
--
2025Q3
124
2.18M
46.47%
-3.07K
2025Q2
112
2.18M
47.13%
-111.10K
2025Q1
106
2.29M
39.48%
-1.15M
2024Q4
98
1.50M
41.86%
-2.03M
2024Q3
82
3.52M
43.30%
+50.30K
2024Q2
68
3.46M
36.20%
+585.47K
2024Q1
43
2.52M
7.33%
+2.06M
2023Q4
40
327.50K
7.25%
-36.20K
2023Q3
40
363.70K
2.81%
+241.80K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Boger (Joshua S)
1.06M
11.43%
--
--
Apr 24, 2025
AWM Investment Company, Inc.
863.20K
9.33%
--
--
Jun 30, 2025
Gregoire (Sylvie L.)
730.79K
7.9%
-1.25K
-0.17%
Apr 24, 2025
Alam (John J)
730.79K
7.9%
+1.25K
+0.17%
Apr 24, 2025
Morgan Stanley & Co. LLC
371.23K
4.01%
+240.63K
+184.25%
Jun 30, 2025
Zavrl (Frank E.)
353.01K
3.82%
--
--
Apr 24, 2025
The Vanguard Group, Inc.
340.02K
3.67%
-38.64K
-10.21%
Jun 30, 2025
Millennium Management LLC
76.08K
0.82%
+76.08K
--
Jun 30, 2025
Geode Capital Management, L.L.C.
54.26K
0.59%
-62.23K
-53.42%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
97.58K
1.05%
-223.90K
-69.65%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.01%
iShares Russell 2000 Growth ETF
0%
Global X Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
iShares Health Innovation Active ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
iShares Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
Proportion0.01%
iShares Russell 2000 Growth ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
iShares Health Innovation Active ETF
Proportion0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Aug 16, 2023
Merger
1.5→1
Aug 16, 2023
Merger
1.5→1
Aug 16, 2023
Merger
1.5→1
Aug 16, 2023
Merger
1.5→1
Apr 18, 2022
Merger
50→1
Apr 18, 2022
Merger
50→1
Date
Type
Ratio
Aug 16, 2023
Merger
1.5→1
Aug 16, 2023
Merger
1.5→1
Aug 16, 2023
Merger
1.5→1
Aug 16, 2023
Merger
1.5→1
Apr 18, 2022
Merger
50→1
Apr 18, 2022
Merger
50→1
Apr 18, 2022
Merger
50→1
Apr 18, 2022
Merger
50→1
FAQs
Who are the top five shareholders of CervoMed Inc?
The top five shareholders of CervoMed Inc are:
Boger (Joshua S) holds 1.06M shares, accounting for 11.43% of the total shares.
AWM Investment Company, Inc. holds 863.20K shares, accounting for 9.33% of the total shares.
Gregoire (Sylvie L.) holds 730.79K shares, accounting for 7.90% of the total shares.
Alam (John J) holds 730.79K shares, accounting for 7.90% of the total shares.
Morgan Stanley & Co. LLC holds 371.23K shares, accounting for 4.01% of the total shares.
Boger (Joshua S) holds 1.06M shares, accounting for 11.43% of the total shares.
AWM Investment Company, Inc. holds 863.20K shares, accounting for 9.33% of the total shares.
Gregoire (Sylvie L.) holds 730.79K shares, accounting for 7.90% of the total shares.
Alam (John J) holds 730.79K shares, accounting for 7.90% of the total shares.
Morgan Stanley & Co. LLC holds 371.23K shares, accounting for 4.01% of the total shares.
What are the top three shareholder types of CervoMed Inc?
The top three shareholder types of CervoMed Inc are:
Boger (Joshua S)
AWM Investment Company, Inc.
Gregoire (Sylvie L.)
Boger (Joshua S)
AWM Investment Company, Inc.
Gregoire (Sylvie L.)
How many institutions hold shares of CervoMed Inc (CRVO)?
As of 2025Q4, 123 institutions hold shares of CervoMed Inc, with a combined market value of approximately 2.18M, accounting for 45.61% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.85%.
What is the biggest source of revenue for CervoMed Inc?
In --, the -- business generated the highest revenue for CervoMed Inc, amounting to -- and accounting for --% of total revenue.
